Ekso Bionics Holdings Inc. news has covered its exoskeleton technology business for medical and industrial applications, including robotic systems designed to support mobility, strength, endurance, and rehabilitation. Company updates include financial results, product and distribution activity, sales trends for Enterprise Health devices and Ekso Indego Personal devices, and rehabilitation offerings such as MediTouch’s BalanceTutor system and eksoUniversity continuing education courses.
Recurring corporate developments also include material agreements, shareholder voting matters, capital-structure disclosures, governance actions, and the completed formation of ChronoScale through a strategic combination involving EKSO Bionics.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced plans to release its second quarter 2022 financial results on July 28, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. Interested investors can access a live webcast via the company’s website. Ekso Bionics, established in 2005, focuses on developing exoskeleton solutions for medical and industrial applications, enhancing human capabilities through innovative wearable technology.
Ekso Bionics Holdings has received 510(k) clearance from the FDA for its EksoNR robotic exoskeleton, marking it as the first device approved for rehabilitation use in Multiple Sclerosis (MS) patients. This approval expands the exoskeleton’s application, previously cleared for stroke and spinal cord injury rehabilitation. With nearly 1 million MS patients in the U.S. and more than 2.8 million globally, EksoNR aims to enhance patient mobility and rehabilitation outcomes.
Available in over 375 centers worldwide, the device has already supported patients in taking nearly 200 million steps.
Ekso Bionics Holdings (Nasdaq: EKSO) announced the appointment of Jerome Wong as Interim Chief Financial Officer following Jack Glenn's resignation effective June 17, 2022. Wong, previously the Controller for five years, brings over 20 years of finance experience. His appointment is expected to provide a seamless transition as the company explores growth opportunities. Glenn's departure is amicable and unrelated to any company disputes. The company continues to innovate in exoskeleton technology, enhancing human capabilities in medical and industrial applications.
Ekso Bionics Holdings, listed under the symbol EKSO, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded presentation will be available on-demand starting at 4:00 AM PT / 7:00 AM ET on May 24, 2022, and can be accessed on the investor section of the company's website.
As a leader in exoskeleton technology, Ekso Bionics focuses on enhancing human strength and mobility for both medical and industrial applications. Established in 2005, the company is headquartered in the San Francisco Bay Area.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported financial results for Q1 2022, achieving $2.6 million in revenue, up from $1.9 million in Q1 2021. The company booked 23 EksoNR units and secured its largest multi-unit order. Gross profit dropped by 2% to $1.2 million, decreasing gross margin to 47% due to increased service costs. Net loss grew to $4.6 million, or $0.36 per share, compared to a loss of $3.7 million in Q1 2021. Cash reserves were $36.2 million as of March 31, 2022, down from $40.4 million at year-end 2021.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced it will release its first quarter 2022 financial results on April 28, 2022, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial outcomes and business developments. Investors can access the live webcast through the company's website, with a replay available for one month post-event. Ekso Bionics specializes in exoskeleton technology, enhancing human strength and mobility in various applications.
Ekso Bionics Holdings reported a record revenue of $4.1 million for Q4 2021, up from $2.3 million in Q4 2020. The company achieved a gross margin of approximately 59%. They booked 30 EksoNR units and posted a reduced net loss of $2.9 million, down from $4.0 million YoY. For the full year, revenue was $11.2 million, marking a 27% increase from 2020. Cash on hand rose to $40.4 million. Management appointed Steven Sherman as CEO and Scott Davis as President/COO, emphasizing their focus on innovation in neurorehabilitation.
Ekso Bionics Holdings (Nasdaq: EKSO) will release its financial results for Q4 and full year 2021 on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. The live webcast will be accessible on the company's website. Founded in 2005, Ekso Bionics specializes in exoskeleton technology aimed at enhancing mobility and strength in medical and industrial sectors.
Ekso Bionics Holdings announced the departure of CEO Jack Peurach effective January 21, 2022, to pursue other endeavors. Steven Sherman, the current Chairman, will step in as CEO starting January 22, 2022, while Scott Davis is promoted to President and COO. The board expressed confidence in future growth after reporting record revenue for Q4, driven by momentum in rehabilitation and industrial segments. Sherman aims to expand the product portfolio and align his compensation with shareholder interests by opting for equity over cash salary.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported record preliminary revenue for Q4 2021 between $3.9 million and $4.1 million, showing a 77% increase from Q4 2020's $2.3 million. Total revenue for fiscal 2021 reached an estimated $11.1 million to $11.3 million, up 26% from $8.9 million in 2020. Cash on hand surged to $40.4 million from $12.9 million a year earlier. CEO Jack Peurach indicated strong growth in both rehabilitation and industrial sectors, enhancing their market presence.